Journal article
Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma
Abstract
Esthesioneuroblastoma is rare, with limited therapeutic options when unresectable or metastatic; however, expression of somatostatin receptors qualifies it for peptide receptor radionuclide therapy (PRRT). We report outcomes of PRRT in esthesioneuroblastoma from 2 referral centers. Methods: Using PRRT databases at 2 European Neuroendocrine Tumor Society Centers of Excellence, cases were sought between 2004 and 2018 of patients who had PRRT with …
Authors
Hasan OK; Ravi Kumar AS; Kong G; Oleinikov K; Ben-Haim S; Grozinsky-Glasberg S; Hicks RJ
Journal
Journal of Nuclear Medicine, Vol. 61, No. 9, pp. 1326–1330
Publisher
Society of Nuclear Medicine
Publication Date
September 2020
DOI
10.2967/jnumed.119.237990
ISSN
0161-5505